News
KURA
11.39
-1.56%
-0.18
Kura Oncology (KURA) Receives a Buy from Leerink Partners
TipRanks · 3d ago
Kura Oncology (KURA) Could Be 61% Below Fair Value After Caspian Therapeutics Deal
Simply Wall St · 3d ago
Kura Oncology (KURA) Receives a Buy from Barclays
TipRanks · 3d ago
Wainwright says Caspian spinout lets Kura refocus on oncology, keeping 50% stake
TipRanks · 4d ago
Kura Oncology Pivots Diabetes Strategy Into $50 Million Subsidiary
Benzinga · 4d ago
Kura Oncology Establishes Caspian Partnership for Cardiometabolic Focus
TipRanks · 4d ago
Kura Oncology launches Caspian Therapeutics
TipRanks · 4d ago
Kura Oncology appoints Jennifer Fulk as CFO
Seeking Alpha · 5d ago
Kura Oncology Names Jennifer Fulk CFO
NASDAQ · 5d ago
Kura Oncology Appoints Jennifer Fulk As CFO, Effective September 8
Benzinga · 5d ago
Press Release: Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer
Dow Jones · 5d ago
Weekly Report: what happened at KURA last week (0831-0904)?
Weekly Report · 6d ago
Is Kura Oncology's (KURA) Zacks Upgrade Quietly Reframing Its Precision Oncology Risk‑Reward Story?
Simply Wall St · 09/02 07:26
KURA Stock Gains 37.6% in a Month: Here's What You Need to Know
NASDAQ · 09/01 13:05
Kura Oncology to Participate in Three Investor Conferences in September
Barchart · 09/01 06:15
Kura Oncology (KURA) Upgraded to Buy: What Does It Mean for the Stock?
NASDAQ · 08/31 16:00
Kura Oncology (KURA) Receives a Buy from Mizuho Securities
TipRanks · 08/31 14:35
Weekly Report: what happened at KURA last week (0824-0828)?
Weekly Report · 08/31 09:26
Cancer Biotech Kura Oncology Rallies to New High After CEO's Stock Purchase
Barron‘s · 08/27 19:27
Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves
NASDAQ · 08/27 14:48
More
Webull provides a variety of real-time KURA stock news. You can receive the latest news about Kura Oncology Inc through multiple platforms. This information may help you make smarter investment decisions.
About KURA
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include KOMZIFTI (Ziftomenib), Tipifarnib, and Darlifarnib (KO-2806). Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a selective investigational inhibitor of the menin-KMT2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is an FTI, is being evaluated in a Phase I first-in-human trial as a monotherapy and in combination with other targeted therapies.